NASDAQ:LGND - Ligand Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$219.82 -1.27 (-0.57 %)
(As of 07/17/2018 05:44 AM ET)
Previous Close$221.09
Today's Range$217.70 - $222.05
52-Week Range$116.44 - $226.35
Volume200,900 shs
Average Volume321,506 shs
Market Capitalization$4.71 billion
P/E Ratio63.17
Dividend YieldN/A
Beta1.08
Ligand Pharmaceuticals logoLigand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations; bazedoxifene for the treatment of postmenopausal osteoporosis; commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta for non-small cell lung cancer. The company's partners programs, which are in clinical development used for the treatment of seizure, coma, cancer, diabetes, cardiovascular diseases, muscle wasting, liver and kidney diseases, and others. It is also developing a small molecule glucagon receptor antagonist for the treatment of Type 2 diabetes mellitus. In addition, the company is involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in San Diego, California.

Receive LGND News and Ratings via Email

Sign-up to receive the latest news and ratings for LGND and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:LGND
CUSIP53220K50
Phone858-550-7500

Debt

Debt-to-Equity Ratio0.03
Current Ratio1.41
Quick Ratio1.37

Price-To-Earnings

Trailing P/E Ratio63.17
Forward P/E Ratio50.77
P/E Growth2.04

Sales & Book Value

Annual Sales$141.10 million
Price / Sales33.18
Cash Flow$3.7486 per share
Price / Cash58.64
Book Value$18.94 per share
Price / Book11.61

Profitability

EPS (Most Recent Fiscal Year)$2.57
Net Income$12.55 million
Net Margins31.40%
Return on Equity19.10%
Return on Assets11.69%

Miscellaneous

Employees39
Outstanding Shares21,300,000
Market Cap$4,709.44

The Truth About Cryptocurrencies

Ligand Pharmaceuticals (NASDAQ:LGND) Frequently Asked Questions

What is Ligand Pharmaceuticals' stock symbol?

Ligand Pharmaceuticals trades on the NASDAQ under the ticker symbol "LGND."

How were Ligand Pharmaceuticals' earnings last quarter?

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) posted its earnings results on Tuesday, May, 8th. The biotechnology company reported $1.55 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $1.29 by $0.26. The biotechnology company had revenue of $56.16 million for the quarter, compared to analysts' expectations of $43.02 million. Ligand Pharmaceuticals had a return on equity of 19.10% and a net margin of 31.40%. Ligand Pharmaceuticals's quarterly revenue was up 91.9% on a year-over-year basis. During the same period last year, the firm earned $0.57 earnings per share. View Ligand Pharmaceuticals' Earnings History.

When is Ligand Pharmaceuticals' next earnings date?

Ligand Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Ligand Pharmaceuticals.

What guidance has Ligand Pharmaceuticals issued on next quarter's earnings?

Ligand Pharmaceuticals issued an update on its FY18 earnings guidance on Wednesday, June, 27th. The company provided EPS guidance of $6.15 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.05. The company issued revenue guidance of $226 million, compared to the consensus revenue estimate of $188.08 million.Ligand Pharmaceuticals also updated its Q2 guidance to $2.32-2.37 EPS.

What price target have analysts set for LGND?

6 brokers have issued twelve-month price objectives for Ligand Pharmaceuticals' shares. Their forecasts range from $105.00 to $230.00. On average, they expect Ligand Pharmaceuticals' share price to reach $165.00 in the next twelve months. This suggests that the stock has a possible downside of 24.9%. View Analyst Ratings for Ligand Pharmaceuticals.

What is the consensus analysts' recommendation for Ligand Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ligand Pharmaceuticals in the last year. There are currently 1 sell rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about Ligand Pharmaceuticals stock?

Here are some recent quotes from research analysts about Ligand Pharmaceuticals stock:
  • 1. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We maintain our Buy rating and are raising our price target to $239 from $182. Our target is based on sum of the parts including: (1) a clinical NPV model of assets in Phase 2 development or greater (currently 30 out of over 165 assets under development); and (2) NPV of current revenues based on our projections for royalties, material sales and collaborative revenue. Below we show our updated clinical NPV valuation model, which accounts for updates to the ‘Next 12’ assets as well as progress for the later stage assets included." (6/28/2018)
  • 2. According to Zacks Investment Research, "Ligand’s  earnings and sales beat estimates in the first quarter of 2018. The company’s Captisol Formulation technology has resulted in partnerships with several leading drug companies like Novartis and Amgen that provide it with funds in the form of milestone and royalty payments. Also, with regard to Ligand’s internal pipeline, there are several candidates in development that could generate future licensing opportunities. Shares of Ligand have outperformed the broader industry in the past year. However, the company derives a substantial portion of its revenues from royalties associated with the sales of Promacta and Kyprolis. Any setback related to either of these products could have a substantial impact. Moreover, Ligand’s dependence on a single supplier to obtain Captisol is concerning." (6/6/2018)

Who are some of Ligand Pharmaceuticals' key competitors?

Who are Ligand Pharmaceuticals' key executives?

Ligand Pharmaceuticals' management team includes the folowing people:
  • Mr. John L. Higgins, CEO & Exec. Director (Age 48)
  • Mr. Matthew W. Foehr, Pres & COO (Age 45)
  • Mr. Matthew Korenberg, Exec. VP of Fin. & CFO (Age 43)
  • Mr. Charles S. Berkman, Sr. VP, Gen. Counsel & Sec. (Age 49)
  • Ms. Audrey Warfield-Graham, Sr. VP of HR

Has Ligand Pharmaceuticals been receiving favorable news coverage?

Press coverage about LGND stock has been trending positive recently, Accern reports. The research group identifies negative and positive press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Ligand Pharmaceuticals earned a news impact score of 0.28 on Accern's scale. They also assigned media stories about the biotechnology company an impact score of 45.15 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

Who are Ligand Pharmaceuticals' major shareholders?

Ligand Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Fisher Asset Management LLC (0.21%), Covenant Asset Management LLC (0.05%), Bank of Montreal Can (0.04%), Xact Kapitalforvaltning AB (0.02%) and Cim LLC (0.00%). Company insiders that own Ligand Pharmaceuticals stock include Charles S Berkman, Jason Aryeh, John L Higgins, John L Lamattina, John W Kozarich, Matthew E Korenberg, Matthew W Foehr, Stephen L Sabba and Todd C Davis. View Institutional Ownership Trends for Ligand Pharmaceuticals.

Which institutional investors are selling Ligand Pharmaceuticals stock?

LGND stock was sold by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC and Bank of Montreal Can. Company insiders that have sold Ligand Pharmaceuticals company stock in the last year include Charles S Berkman, Jason Aryeh, John L Higgins, John L Lamattina, John W Kozarich, Matthew E Korenberg, Matthew W Foehr, Stephen L Sabba and Todd C Davis. View Insider Buying and Selling for Ligand Pharmaceuticals.

Which institutional investors are buying Ligand Pharmaceuticals stock?

LGND stock was purchased by a variety of institutional investors in the last quarter, including Covenant Asset Management LLC, Cim LLC and Xact Kapitalforvaltning AB. View Insider Buying and Selling for Ligand Pharmaceuticals.

How do I buy shares of Ligand Pharmaceuticals?

Shares of LGND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ligand Pharmaceuticals' stock price today?

One share of LGND stock can currently be purchased for approximately $219.82.

How big of a company is Ligand Pharmaceuticals?

Ligand Pharmaceuticals has a market capitalization of $4.71 billion and generates $141.10 million in revenue each year. The biotechnology company earns $12.55 million in net income (profit) each year or $2.57 on an earnings per share basis. Ligand Pharmaceuticals employs 39 workers across the globe.

How can I contact Ligand Pharmaceuticals?

Ligand Pharmaceuticals' mailing address is 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-550-7500 or via email at [email protected]


MarketBeat Community Rating for Ligand Pharmaceuticals (NASDAQ LGND)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  356 (Vote Outperform)
Underperform Votes:  211 (Vote Underperform)
Total Votes:  567
MarketBeat's community ratings are surveys of what our community members think about Ligand Pharmaceuticals and other stocks. Vote "Outperform" if you believe LGND will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LGND will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.